Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
July 01, 2019
EBioMedicine

CTD2 scientists at Stanford University showed that radiomic analysis of computed tomography could be used to identify molecular subtypes of head and neck squamous cell carcinomas.

CTD²
July 01, 2019
Nature Genetics

CTD2 scientists at Stanford University developed SCIMET, an analytical framework that provides quantitative measurement of dynamics of metastasis in a patient-specific manner; indicates early dissemination of colorectal cancer in the majority of the patients.

CTD²
June 13, 2019
Cell Stem Cell

CTD2 scientists at UCSF showed that neuroepithelial stem cells derived from normal induced pluripotent stem cells could be a powerful experimental resource to evaluate genetic mutations in medulloblastoma.

CTD²
June 10, 2019
Cancer Cell

CTD2 scientists at OHSU demonstrated that sequential therapy with PARP and either WEE1 or ATR inhibitors is effective and potentially less toxic in multiple relevant cancer models.

CTD²
June 04, 2019
Cell Chemical Biology

Scientists at the Broad Institute CTD2 Center identified 6-phosphogluconate dehydrogenase, a cytosolic enzyme as a link between carbohydrate metabolism and protein secretion.

CTD²
June 03, 2019
Nature Communications

Integrative genomic analyses of expression profiling, CRISPR-Cas9 and ORF/cDNA, identifies cell-essential genes suppressed by BET-bromodomain inhibition. The study suggests the use of cell-cycle inhibitors in combination with BET-bromodomain inhibitors to treat MYC-amplified medulloblastoma.

CTD²
June 01, 2019
Gut

Columbia CTD2 researchers developed ADVOCATE, a computational model to analyze gene expression data of epithelial and stromal pancreatic ductal adenocarcinoma samples. These studies indicated a novel classification signature which could facilitate the development of precision oncology approaches.

CTD²
May 16, 2019
Nature Communications

Scientists at the UCSD CTD2 Center showed that epigenetic dysregulation and silencing are associated with chromatin repression and aberrant hypermethylation at the transcription start site in HPV-related oral cancers; independent of CpG island and is associated with MYC pathway activation.

CTD²
May 01, 2019
Gynecologic Oncology

CTD2 researchers showed that ovarian cancer patients with CD3+ tumor infiltrating lymphocytes and homologous recombination deficiency have improved survival.

CTD²
May 01, 2019
Nature Medicine

Researchers profiled 225 metabolites in 928 cell lines from more than 20 cancer types in the cancer cell line encyclopedia using liquid chromatography – mass spectrometry.

Pages

CSVXML